Science · 2013 · 811 citations · 39 references
Life SciencesBiotechnologyImmunologyAntibody EngineeringProtein EngineeringVaccinologyAntibody Specificity EngineeringAntigen DesignHiv Vaccine DevelopmentLigand BindingVaccine Antigen DesignVaccine Antigen DiscoveryAntibodiesB Cell Germline ActivationB-cell EpitopesGermline Targeting ImmunogensHiv Envelope Glycoprotein AntigensNanoparticlesStructural Basis Of Receptor RecognitionVaccine Immunogen Design
Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority. Potent VRC01-class bNAbs against the CD4 binding site of HIV gp120 have been isolated from HIV-1-infected individuals; however, such bNAbs have not been induced by vaccination. Wild-type gp120 proteins lack detectable affinity for predicted germline precursors of VRC01-class bNAbs, making them poor immunogens to prime a VRC01-class response. We employed computation-guided, in vitro screening to engineer a germline-targeting gp120 outer domain immunogen that binds to multiple VRC01-class bNAbs and germline precursors, and elucidated germline binding crystallographically. When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanoparticles have promise as a vaccine prime. In principle, germline-targeting strategies could be applied to other epitopes and pathogens.
39
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text